Helmholtz Gemeinschaft


Browse by Journal Title

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type
Jump to: 2022 | 2020 | 2018 | 2015 | 2009 | 2007 | 2006 | 2004 | 2003 | 2002 | 2001 | 1997 | 1993 | 1992


Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.
Ballhausen, A. and Ben Hamza, A. and Welters, C. and Dietze, K. and Bullinger, L. and Rahn, H.P. and Hartmann, S. and Hansmann, M.L. and Hansmann, L.
Cancer Immunology Immunotherapy 10 August 2022 (In Press)

Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes.
Kursunel, M.A. and Taskiran, E.Z. and Tavukcuoglu, E. and Yanik, H. and Demirag, F. and Karaosmanoglu, B. and Ozbay, F.G. and Uner, A. and Esendagli, D. and Kizilgoz, D. and Yilmaz, U. and Esendagli, G.
Cancer Immunology Immunotherapy 71 (2): 445-459. February 2022


Prostaglandin E(2) in a TLR3- and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8(+) T cells.
Gierlich, P. and Lex, V. and Technau, A. and Keupp, A. and Morper, L. and Glunz, A. and Sennholz, H. and Rachor, J. and Sauer, S. and Marcu, A. and Grigoleit, G.U. and Wölfl, M. and Schlegel, P.G. and Eyrich, M.
Cancer Immunology Immunotherapy 69 (6): 1029-1042. June 2020


Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.
Weber, A.N.R. and Cardona Gloria, Y. and Çınar, Ö. and Reinhardt, H.C. and Pezzutto, A. and Wolz, O.O.
Cancer Immunology Immunotherapy 67 (11): 1797-1807. November 2018


Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.
Stermann, A. and Huebener, N. and Seidel, D. and Fest, S. and Eschenburg, G. and Stauder, M. and Schramm, A. and Eggert, A. and Lode, H.N.
Cancer Immunology Immunotherapy 64 (10): 1215-1227. October 2015

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Seidel, D. and Shibina, A. and Siebert, N. and Wels, W.S. and Reynolds, C.P. and Huebener, N. and Lode, H.N.
Cancer Immunology Immunotherapy 64 (5): 621-634. May 2015


TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008.
Uckert, W. and Schumacher, T.N.
Cancer Immunology Immunotherapy 58 (5): 809-822. May 2009

HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
Vertuani, S. and Triulzi, C. and Roos, A.K. and Charo, J. and Norell, H. and Lemonnier, F. and Pisa, P. and Seliger, B. and Kiessling, R.
Cancer Immunology Immunotherapy 58 (5): 653-664. May 2009

Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial.
Schulze, T. and Kemmner, W. and Weitz, J. and Wernecke, K.D. and Schirrmacher, V. and Schlag, P.M.
Cancer Immunology Immunotherapy 58 (1): 61-69. January 2009


The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs.
Ravn, P. and Stahn, R. and Danielczyk, A. and Faulstich, D. and Karsten, U. and Goletz, S.
Cancer Immunology Immunotherapy 56 (9): 1345-1357. September 2007

Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells.
Na, I.K. and Keilholz, U. and Letsch, A. and Bauer, S. and Asemissen, A.M. and Nagorsen, D. and Thiel, E. and Scheibenbogen, C.
Cancer Immunology Immunotherapy 56 (3): 391-396. March 2007


PankoMab: a potent new generation anti-tumour MUC1 antibody.
Danielczyk, A. and Stahn, R. and Faulstich, D. and Loeffler, A. and Maerten, A. and Karsten, U. and Goletz, S.
Cancer Immunology Immunotherapy 55 (11): 1337-1347. November 2006

Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Schlereth, B. and Kleindienst, P. and Fichtner, I. and Lorenczewski, G. and Brischwein, K. and Lippold, S. and Silva, A.D. and Locher, M. and Kischel, R. and Lutterbuese, R. and Kufer, P. and Baeuerle, P.A.
Cancer Immunology Immunotherapy 55 : 785-796. July 2006

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Schlereth, B. and Quadt, C. and Dreier, T. and Kufer, P. and Lorenczewski, G. and Prang, N. and Brandl, C. and Lippold, S. and Cobb, K. and Brasky, K. and Leo, E. and Bargou, R. and Murthy, K. and Baeuerle, P.A.
Cancer Immunology Immunotherapy 55 : 503-514. May 2006


T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent.
Gruen, M. and Bommert, K. and Bargou, R.C.
Cancer Immunology Immunotherapy 53 (7): 625-632. 1 January 2004


Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties.
Westermann, J. and Koerner, I.J. and Kopp, J. and Kurz, S. and Zenke, M. and Doerken, B. and Pezzutto, A.
Cancer Immunology Immunotherapy 52 (3): 194-198. March 2003


Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial.
Pecher, G. and Haering, A. and Kaiser, L. and Thiel, E.
Cancer Immunology Immunotherapy 51 (11-12): 669-673. December 2002


Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1).
Johnen, H. and Kulbe, H. and Pecher, G.
Cancer Immunology Immunotherapy 50 : 356-360. 1 January 2001

Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann, J. and Reich, G. and Kopp, J. and Haus, U. and Doerken, D. and Pezzutto, A.
Cancer Immunology Immunotherapy 49 : 613-620. 1 January 2001


A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis.
Jerome, K.R. and Kirk, A.D. and Pecher, G. and Ferguson, W.W. and Finn, O.J.
Cancer Immunology Immunotherapy 43 : 355-360. 1 January 1997


Monoclonal antibody uptake in B-cell lymphomas: experimental studies in nude mouse xenografts.
Schmid, J. and Moeller, P. and Moldenhauer, G. and Doerken, B. and Bihl, H. and Matzku, S.
Cancer Immunology Immunotherapy 36 : 274-280. 1 January 1993

In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells.
Stoeck, M. and Marland-Noske, C. and Manasterski, M. and Zawatzky, R. and Horn, S. and Moebus, V. and Schlag, P.M. and Schirrmacher, V.
Cancer Immunology Immunotherapy 37 : 240-244. 1 January 1993


Active specific immunotherapy with Newcastle-disease-virus modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.
Schlag, P.M. and Manasterski, M. and Gerneth, T. and Hohenberger, P. and Dueck, M. and Herfarth, C. and Liebrich, W. and Schirrmacher, V.
Cancer Immunology Immunotherapy 35 (5): 325-330. 1 May 1992

This list was generated on Tue Nov 29 02:35:48 2022 CET.
Open Access
MDC Library